📊 BIXT Key Takeaways
Investment Thesis
Bioxytran exhibits critical financial distress with negative stockholders equity of -$2.9M, indicating the company is technically insolvent. Revenue has collapsed 22.5% YoY to just $33.6K while operating losses continue to deteriorate, with negative operating cash flow of -$289.5K consuming cash reserves. The company faces imminent solvency risk with minimal liquid assets of $14.5K against $3.1M in liabilities and insufficient operational momentum for turnaround.
BIXT Strengths
- Positive gross margin of 30.5% suggests underlying product economics are viable if revenue can scale
- Marginal improvement in net loss of 0.6% and diluted EPS improvement of 33.3% YoY shows minimal stabilization
- Pharmaceutical sector positioning offers potential for value creation if pipeline development succeeds
BIXT Risks
- Negative stockholders equity of -$2.9M indicates technical insolvency and existential solvency risk
- Revenue base of $33.6K is critically small and declining, insufficient to support $3.1M liability structure
- Negative operating cash flow of -$289.5K with only $14.5K in cash reserves suggests runway of less than 2 weeks at current burn rate
- Current ratio of 0.00x indicates no ability to meet short-term obligations
- No insider trading activity in 90 days suggests loss of management confidence or dormant operations
Key Metrics to Watch
- Monthly burn rate and cash runway until depletion
- Revenue growth rate and ability to achieve $500K+ quarterly revenue
- Stockholders equity trajectory and path to positive net worth
- Operating cash flow inflection and achievement of positive monthly cash generation
BIXT Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BIXT Profitability Ratios
BIXT vs Healthcare Sector
How BIOXYTRAN, INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BIXT Balance Sheet & Liquidity
BIXT 5-Year Financial Trend
5-Year Trend Summary: BIOXYTRAN, INC's revenue has declined by 41% over the 5-year period, indicating business contraction. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
BIXT Growth Metrics (YoY)
BIXT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2018 | $20.3K | -$115.7K | N/A |
| Q1 2018 | $7.4K | -$29.6K | N/A |
| Q3 2017 | $101.1K | $48.9K | N/A |
| Q2 2017 | $39.5K | -$163.0K | N/A |
| Q1 2017 | $7.4K | -$64.6K | N/A |
| Q3 2016 | $101.1K | -$30.1K | N/A |
| Q2 2016 | $55.6K | -$163.0K | N/A |
| Q1 2016 | $31.5K | -$39.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BIXT Capital Allocation
BIXT SEC Filings
Access official SEC EDGAR filings for BIOXYTRAN, INC (CIK: 0001445815)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIXT
What is the AI rating for BIXT?
BIOXYTRAN, INC (BIXT) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIXT's key strengths?
Positive gross margin of 30.5% suggests underlying product economics are viable if revenue can scale. Marginal improvement in net loss of 0.6% and diluted EPS improvement of 33.3% YoY shows minimal stabilization.
What are the risks of investing in BIXT?
Negative stockholders equity of -$2.9M indicates technical insolvency and existential solvency risk. Revenue base of $33.6K is critically small and declining, insufficient to support $3.1M liability structure.
What is BIXT's revenue and growth?
BIOXYTRAN, INC reported revenue of $33.6K.
Does BIXT pay dividends?
BIOXYTRAN, INC does not currently pay dividends.
Where can I find BIXT SEC filings?
Official SEC filings for BIOXYTRAN, INC (CIK: 0001445815) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIXT's EPS?
BIOXYTRAN, INC has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.